Application of a drug expressing the PCNP gene in the fight against influenza virus

The preparation of PCNP nucleoprotein drugs using a baculovirus expression system addresses the shortcomings of existing anti-influenza virus methods, achieving highly efficient protection against H1N1 and H3N2 influenza viruses, reducing production costs, and improving mouse survival and weight maintenance.

CN115869423BActive Publication Date: 2026-11-17ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211428471.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-15
Publication Date
2026-11-17
Estimated Expiration
2042-11-15

AI Technical Summary

Technical Problem

There is a lack of effective antiviral measures in the current technology, especially insufficient protection against H1N1 and H3N2 influenza viruses.

Method used

PCNP nucleoprotein was expressed using a baculovirus expression system. The PCNP gene was cloned using a baculovirus expression vector and the PCNP protein was expressed and purified in insect cells for use in the preparation of a drug overexpressing the PCNP gene. Its anti-influenza activity was verified in a mouse challenge protection experiment.

Benefits of technology

It significantly increased the expression level and activity of PCNP protein, reduced production costs, and provided good protection against H1N1 and H3N2 influenza virus attacks, improving the survival rate and weight maintenance ability of mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115869423B_ABST
    Figure CN115869423B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of gene therapy, and particularly relates to the application of a drug expressing the PCNP gene in the fight against influenza viruses. This invention also provides a method for preparing the PCNP nucleoprotein and its anti-influenza virus activity. This study used a baculovirus expression system to express the PCNP nucleoprotein and performed Western blotting (WB) verification. Mouse experiments demonstrated that this protein can improve the protection efficiency against H1N1 and H3N2 viruses, and can be used to treat or prevent infection with different subtypes of influenza viruses. The method for preparing the PCNP nucleoprotein of this invention is simple, low-cost, and has good therapeutic effects, and can be used for the prevention and treatment of influenza viruses, providing assistance in controlling the spread of influenza viruses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of gene therapy, and in particular relates to the application of a drug that overexpresses the PCNP gene in the fight against influenza virus. Background Technology

[0002] PCNP (PEST-containing nuclear protein), a newly discovered nuclear protein containing the PEST sequence, was first indirectly reported by Japanese scientists in 2004 as a substrate of the ubiquitin ligase NIRF (Np95 / ICBP90-like ring figer protein). PCNP and NIRF together constitute a novel signal transduction pathway closely related to cell cycle regulation and cell proliferation. PCNP is mainly located in the cell nucleus. This novel ring-shaped protein is a protein ligase with ubiquitination capabilities, participating in the ubiquitination pathway of protein degradation. Currently, there are relatively few reports on PCNP, but there is relatively more research on the PEST domain. PEST plays a regulatory role in cell cycle and proliferation, and is also related to chromosome stability, tumorigenesis, and immune system diseases.

[0003] Influenza is one of the most serious global infectious diseases caused by influenza viruses. Each influenza outbreak causes enormous damage to the socio-economic situation and human health. Influenza A viruses belong to the Orthomyxovirus family and have a wide host range, including humans, mammals, and birds. They can cause seasonal influenza and avian influenza. H1N1 and H3N2, as representative viruses, have participated in numerous influenza outbreaks, causing significant inconvenience to people's lives.

[0004] PCNP, a disease gene related to the immune system, has been reported to inhibit the growth of human liver cancer cells and human neuroblastoma. We explored its application in anti-influenza studies by expressing the protein through a baculovirus expression system and conducting immunoprotective experiments to verify whether PCNP can protect against influenza virus attack. Summary of the Invention

[0005] To address the technical problem of this invention, the present invention provides the application of a drug overexpressing the PCNP gene in the fight against influenza virus. The drug is produced by cloning the PCNP gene into a baculovirus expression vector, expressing the PCNP protein using a baculovirus expression system, and then verifying the anti-influenza activity of PCNP through a mouse challenge protection experiment.

[0006] To achieve the objectives of this invention, the PCNP gene-expressing drug of this invention expresses PCNP nucleoprotein via a baculovirus expression system as follows: RNA is extracted from mouse lung tissue and reverse transcribed into cDNA; PCR amplification is performed using primers for PCNP nucleoprotein with cDNA as a template to obtain the PCNP gene fragment; the PCNP gene is cloned into the pFastBac1 vector, transfected into insect cells to obtain a recombinant baculovirus; insect cells are inoculated with the virus, and the expression and purification are performed to obtain the protein.

[0007] Specifically, the primer sequences for the PCNP nuclear protein are as follows:

[0008] F:CCCGGAATTCATGGTTGTTGGGCGGGGTCGTGACGTCCTTGGCGTGGCT (SEQ ID NO: 1);

[0009] R: CCCAAGCTTTTAGTGATGATGGTGGTGATGATTGTCTTGGTCATGGACAT (SEQ ID NO: 2).

[0010] The restriction endonucleases for digesting the PCNP gene and pFastBac1 vector are EcoRI and HindIII.

[0011] The purification method is nickel column affinity chromatography.

[0012] The method for preparing the drug expressing the PCNP gene includes the following steps:

[0013] Step 1: Construction of recombinant baculovirus Bacmid plasmid: The obtained PCNP gene and the gene of the pFastBac1 vector were subjected to multiple cloning site analysis. Two restriction endonucleases provided on the vector but not in the target fragment were selected: EcoRI and HindIII. After double digestion, the recovered target fragment was inserted into the insect cell expression vector pFastBac1 and transformed into Escherichia coli DH10Bac competent cells.

[0014] Step 2, rescue of recombinant baculovirus: Insect cells were transfected with the recombinant baculovirus Bacmid plasmid to rescue and obtain recombinant baculovirus.

[0015] Step 3: Large-scale expression and purification of protein: Infect insect cells with the obtained recombinant baculovirus at MOI=3. Harvest the supernatant after 3 days and purify it by nickel column affinity chromatography to obtain PCNP nucleoprotein.

[0016] The specific operation of step one is as follows: Take 1 μl of pFastBac1-PCNP and add it to 50 μl of DH10Bac competent cells, incubate on ice for 30 min, heat shock at 42℃ for 45 s, incubate on ice for 2 min, add 1 ml of antibiotic-free LB medium, and incubate at 37℃ for 48 h. Pick white colonies, add LB medium, and incubate at 37℃ on a shaker at 200 rpm / min for 12 h. Extract plasmid DNA and perform PCR identification. The positive plasmid that is correctly identified is the recombinant baculovirus Bacmid plasmid.

[0017] In step two, transfection is performed when the insect cells have reached a cell confluence of more than 80%.

[0018] The insect cells used in steps two and three are Sf9 cells.

[0019] The purification procedure in step three involves adding the supernatant to a nickel column to ensure complete binding, then washing with 25 mmol of imidazole, and finally eluting with 250 mmol of imidazole.

[0020] The PCNP protein described in this invention can be used as a drug that overexpresses the PCNP gene in the fight against influenza.

[0021] The significant technical effects of this invention.

[0022] The baculovirus expression system used in our research group has high expression levels and good product activity. In addition, we can further enhance the expression level by performing targeted sequence optimization based on the original gene. This method has the advantage of large-scale production, high yield, which can effectively reduce its production cost, and has a good protective effect against H1N1 and H3N2 influenza viruses. Attached Figure Description

[0023] Figure 1 After transfecting sF9 cells with the pFastBac1-PCNP plasmid, the expression of PCNP protein was verified by SDS-PAGE of the P3 generation cells.

[0024] Figure 2 The protein composition of each component in the cell stock solution, flow buffer, and elution buffer during the nickel column purification of PCNP protein is shown below: 1. Marker, 2. Cell lysis buffer, 3. Flow buffer, 4. 25 mM imidazole wash buffer, 5. 50 mM imidazole wash buffer, 6. 100 mM imidazole wash buffer, 7. 100 mM imidazole wash buffer, and 8. 250 mM imidazole wash buffer.

[0025] Figure 3 After nickel column purification of PCNP protein, pure PCNP protein can be obtained; including 1. Marker, 2. PCNP protein after dialysis, and 3. PCNP protein after dialysis.

[0026] Figure 4 The survival rate and weight change rate of mice after challenge with H1N1 influenza virus (mouse-adapted A / Changchun / 01 / 2009) and H3N2 virus (mouse-adapted A / baikal teal / Shanghai / SH-89 / 2013) are shown. A and B are the weight change (A) and survival rate change (B) of mice after H1N1 challenge, respectively, and C and D are the weight change (C) and survival rate change (D) of mice after H3N2 challenge, respectively. Specific implementation methods

[0027] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.

[0028] Example 1: Expression and Identification of PCNP Nucleoprotein

[0029] Materials: E. coli DH5α and E. coli DH10Bac were preserved in our laboratory. Donor plasmid pFastBac1 was purchased from Invitrogen. Insect cell transfection kits were purchased from Invitrogen. Endonucleases were purchased from Thermo Fisher Scientific. Genome extraction kits were purchased from Axygen. Sf-900 II SFM was purchased from Thermo Fisher Scientific. Antibiotics were purchased from Solarbio. PCNP polyclonal antibody was purchased from Proteintech.

[0030] 2 methods

[0031] 2.1 RNA was extracted from mouse lung tissue and reverse transcribed into cDNA. The cDNA was then used as a template for PCR amplification using primers for PCNP nucleoprotein (F: CCCGGAATTCATGGTTGTTGGGCGGGGTCGTGACGTCCTTGGCGTGGCT, R: CCCAAGCTTTTAG TGATGATGGTGGTGATGATTGTCTTGGTCATGGACAT). The PCNP gene fragment was obtained.

[0032] 2.2 Construction of Recombinant Shuttle Plasmid

[0033] The obtained PCNP gene was cloned into plasmid pFastBac1 based on the EcoR1 and HindIII restriction sites, transformed into E. coli DH5α competent cells, plated and cultured overnight, screened for positive bacteria, and then the plasmid was extracted for PCR, sequencing, and restriction enzyme digestion identification to obtain the correct pFastBac1-PCNP plasmid. PCNP FR were used as upstream and downstream primers for PCR identification of the PCNP fragment.

[0034] 2.3 Construction of recombinant rod-shaped plasmids

[0035] DH10Bac competent cells were transformed with pFastBac1 PCNP plasmid. White colonies were selected from the resulting blue-white colonies, and the plasmid was extracted and confirmed by PCR to be correct, thus obtaining the recombinant rod plasmid PCNP Bacmid.

[0036] 2.4 Rescuing Recombinant Baculovirus

[0037] Positive Bacmid samples were transfected into sf9 cells using the Cellreagent transfection kit. After three days of incubation at 27°C, cell culture supernatant P1 was collected. P1 was then seeded into new sf9 cells at a volume of 3% and cultured for an amplification of viral virulence. After three days of culture, P2 generation supernatant was collected and seeded into new sf9 cells at a volume of 3%. After three days of culture, P3 generation supernatant was collected. DNA was extracted from the P3 generation supernatant for PCR verification, and morphological changes in P3 cells were observed and recorded. After infection of sf9 cells with recombinant Bacmid, microscopic examination revealed that cell proliferation ceased, granular bodies appeared around the cells, and cell viability decreased.

[0038] 2.5 Large-scale expression and purification

[0039] P3 generation baculovirus was used to inoculate large numbers of cultured suspension Sf9 cells at an MOI of 3. Four days later, the cell culture medium was harvested, and after a series of steps including cell debris removal, viral supernatant lysis, nickel-coated protein purification, and PBS deimidazole treatment, purified PCNP protein was obtained. Protein identification after PCNP transfection into Sf9 cells is shown in [link to relevant documentation]. Figure 1 The protein composition of each component in the cell stock solution, transfer buffer, and elution buffer during PCNP protein nickel column purification is shown in the following figures. Figure 2 As can be seen, PCNP protein can be obtained after elution with imidazole.

[0040] 2.6 Western blot validation

[0041] Western blot analysis using rabbit polyclonal antibody as the primary antibody revealed a band at approximately 26 kDa for the PCNP protein. Figure 3 The results indicate that PCNP protein is expressed correctly.

[0042] Example 2: Anti-influenza effect of PCNP nucleoprotein

[0043] 1. Materials: The BCA protein detection kit was purchased from Thermo Fisher Scientific, and 6-8 week old female BALB / c mice were purchased from Beijing Vital River Pharmaceutical Co., Ltd.

[0044] 2. Experimental Methods

[0045] Immunization and Challenge: Protein concentration was detected using a BCA assay kit. Purified PCNP protein was used in a mouse challenge protection experiment. Each mouse received an intraperitoneal injection of 40 μg of PCNP protein 24 hours before challenge, and an intravenous injection of 40 μg of PCNP protein simultaneously with challenge. Mice were challenged with 10 MLD50 of H1N1 influenza virus (mouse-adapted A / Changchun / 01 / 2009) and H3N2 virus (mouse-adapted A / baikal teal / Shanghai / SH-89 / 2013). Daily changes in mouse body weight and survival rate were observed. All experimental conditions and procedures adhered to the ethical guidelines of the International Association for the Study of Pain.

[0046] See results Figure 4 After H1N1 challenge, the survival rate of the PCNP group was 40%, with no significant change in mouse weight. In the Mock group, no mice survived, and their weight decreased significantly, leading to death by day 7. After H3N2 challenge, the survival rate of the PCNP group was 20%, with a slight decrease in mouse weight. In the Mock group, no mice survived, and their weight decreased significantly, leading to death by day 7. These mouse challenge experiments demonstrate that the PCNP protein can provide partial protection against influenza virus challenge.

Claims

1. The application of a PCNP protein in the preparation of drugs against H1N1 and H3N2 influenza viruses, characterized in that, The method for preparing the PCNP protein includes the following steps: Step 1: Preparation of PCNP gene fragment: RNA was extracted from mouse lung tissue and reverse transcribed into cDNA. Using primers for PCNP protein, PCR amplification was performed with cDNA as a template. The operation method was 95℃ for 5 min, followed by 30 cycles of 95℃ for 30 s, 56℃ for 90 s, and 72℃ for 40 s to obtain the PCNP gene fragment. The primer sequences for the PCNP protein are: F: CCCGGAATTCATGGTTGTTGGGCGGGGTCGTGACGTCCTTGGCGTGGCT (SEQ ID NO:1); R: CCCAAGCTTTTAGTGATGATGGTGGTGATGATTGTCTTGGTCATGGACAT (SEQ ID NO:2). Step 2: Construction of recombinant baculovirus Bacmid plasmid: The obtained PCNP gene and the gene of the pFastBac1 vector were analyzed for multiple cloning sites. Two restriction endonucleases provided on the vector but not in the target fragment were selected: EcoRI and HindIII. After double digestion, the recovered target fragment was inserted into the Sf9 cell expression vector pFastBac1 and transformed into E. coli DH10Bac competent cells. The procedure is as follows: 1 μl of pFastBac1-PCNP was added to 50 μl of DH10Bac competent cells, incubated on ice for 30 min, heat-shocked at 42℃ for 45 s, incubated on ice for 2 min, and then 1 ml of antibiotic-free LB medium was added. The cells were cultured at 37℃ for 48 h. White colonies were picked, added to LB medium, and cultured on a shaker at 37℃ and 200 rpm / min for 12 h. Plasmid DNA was extracted and PCR was performed. The correctly identified positive plasmid is the recombinant baculovirus Bacmid plasmid. Step 3, rescue of recombinant baculovirus: Sf9 cells were transfected with the recombinant baculovirus Bacmid plasmid to rescue and obtain recombinant baculovirus; Step 4: Large-scale expression and purification of protein: The obtained recombinant baculovirus was used to infect Sf9 cells at MOI=3. After 3 days, the supernatant was harvested and added to a nickel column to allow it to fully bind. Then, it was washed with 25 mmol of imidazole and eluted with 250 mmol of imidazole. The purified PCNP protein was obtained.

2. The use of the PCNP protein as described in claim 1 in the preparation of drugs against H1N1 and H3N2 influenza viruses, characterized in that, In step three, the Sf9 cells achieved a cell confluence of over 80%.

Citation Information

Patent Citations

  • Preparation method and use of medicine over-expressing PCNP gene

    CN107630027A

  • PCNP gene overexpression method and application thereof in treatment of human liver cancer

    CN113136402A